A number of other analysts also recently weighed in on the company. TheStreet downgraded Retrophin from a c- rating to a d+ rating in a report on Friday, February 22nd. Svb Leerink reaffirmed an outperform rating on shares of Retrophin in a research report on Tuesday, February 26th. ValuEngine cut shares of Retrophin from a strong-buy rating to a buy rating in a research report on Thursday, January 17th. Zacks Investment Research raised shares of Retrophin from a strong sell rating to a hold rating in a research report on Wednesday, February 27th. Finally, William Blair reaffirmed an outperform rating on shares of Retrophin in a research report on Wednesday, April 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $50.50.
NASDAQ RTRX opened at $20.05 on Friday. The firm has a market capitalization of $830.81 million, a P/E ratio of -7.89 and a beta of 1.02. Retrophin has a twelve month low of $19.57 and a twelve month high of $33.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 4.74 and a quick ratio of 4.68.
Retrophin (NASDAQ:RTRX) last posted its quarterly earnings data on Tuesday, February 26th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.42. The business had revenue of $43.77 million during the quarter, compared to the consensus estimate of $43.54 million. Retrophin had a negative return on equity of 33.53% and a negative net margin of 62.51%. Retrophin’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.07 earnings per share. On average, sell-side analysts anticipate that Retrophin will post -2.47 EPS for the current fiscal year.
In other Retrophin news, SVP William E. Rote sold 1,250 shares of the company’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $21.52, for a total transaction of $26,900.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Elizabeth E. Reed sold 1,769 shares of the stock in a transaction dated Tuesday, February 12th. The stock was sold at an average price of $21.44, for a total transaction of $37,927.36. Following the transaction, the senior vice president now directly owns 15,442 shares in the company, valued at approximately $331,076.48. The disclosure for this sale can be found here. Insiders have sold 12,917 shares of company stock worth $277,140 in the last ninety days. Insiders own 3.67% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in RTRX. Bank of America Corp DE boosted its position in shares of Retrophin by 114.4% during the 4th quarter. Bank of America Corp DE now owns 1,223,705 shares of the biopharmaceutical company’s stock worth $27,693,000 after purchasing an additional 652,895 shares in the last quarter. Macquarie Group Ltd. boosted its position in shares of Retrophin by 17.6% during the 4th quarter. Macquarie Group Ltd. now owns 2,265,924 shares of the biopharmaceutical company’s stock worth $51,278,000 after purchasing an additional 339,588 shares in the last quarter. Two Sigma Investments LP boosted its position in shares of Retrophin by 247.9% during the 4th quarter. Two Sigma Investments LP now owns 300,873 shares of the biopharmaceutical company’s stock worth $6,809,000 after purchasing an additional 214,392 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its position in shares of Retrophin by 30.6% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 777,520 shares of the biopharmaceutical company’s stock worth $17,595,000 after purchasing an additional 182,318 shares in the last quarter. Finally, Handelsbanken Fonder AB boosted its position in shares of Retrophin by 66.3% during the 4th quarter. Handelsbanken Fonder AB now owns 443,916 shares of the biopharmaceutical company’s stock worth $10,046,000 after purchasing an additional 176,916 shares in the last quarter.
Retrophin Company Profile
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Further Reading: Special Dividends
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.